Eldepryl Patient, Information, Instructions - Selegiline

Eldepryl Patient, Information, Instructions - Selegiline

PATIENT INFORMATION

Patients should be advised of the possible need to reduce levodopa dosage after the initiation of selegiline hydrochloride therapy.

Patients (or their families if the patient is incompetent) should be advised not to exceed the daily recommended dose of 10 mg. The risk of using higher daily doses of selegiline should be explained, and a brief description of the 'cheese reaction' provided. While hypertensive reactions with selegiline associated with dietary influences have not been reported, documented experience is limited.

Consequently, it may be useful to inform patients (or their families) about the signs and symptoms associated with M.O. induced hypertensive reactions. In particular, patients should be urged to report, immediately, any severe headache or other atypical or unusual symptoms not previously experienced.